| Dr Debra Lee Kaysen, PHD | |
|
300 Pasteur Dr, Stanford, CA 94305-2200 | |
| (650) 723-4000 | |
| Not Available |
| Full Name | Dr Debra Lee Kaysen |
|---|---|
| Gender | Female |
| Speciality | Psychologist - Clinical |
| Location | 300 Pasteur Dr, Stanford, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073698882 | NPI | - | NPPES |
| 2001415 | Other | INTERNAL ID-MOTOR VEHICLE ID | |
| 8434193 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC0700X | Psychologist - Clinical | PSY31348 (California) | Primary |
| Entity Name | Stanford Health Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437292927 PECOS PAC ID: 6709797491 Enrollment ID: O20031124000348 |
News Archive
TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today announces the receipt of EUR 1.7 million from Bpifrance.
Fluxion Biosciences, Inc. announced the presentation of the first pilot study results aimed at isolating circulating tumor cells (CTCs) from early stage non-small cell lung cancer (NSCLC) patients obtained in collaboration with Dr. Max Diehn's lab at Stanford University. CTCs are cells that disseminate from primary tumors and contribute to the spread of the disease to other parts of the body.
Patients with acute coronary syndrome undergoing angioplasty who received the anticoagulant drug bivalirudin did not show significant improvements in either of two co-primary endpoints-a composite of rate of death, heart attack or stroke at 30 days, or a composite of those events plus major bleeding-as compared to patients receiving standard anticoagulation therapy, according to a study presented at the American College of Cardiology's 64th Annual Scientific Session.
Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has approved XIAFLEX (collagenase clostridium histolyticum, or CCH), an in-office, biologic for the treatment of Peyronie's disease. XIAFLEX is the first and only FDA-approved treatment proven effective for PD in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy.
› Verified 9 days ago
| Entity Name | Lpch Medical Group Div Of Lucile |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417907940 PECOS PAC ID: 0840298543 Enrollment ID: O20061113000232 |
News Archive
TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today announces the receipt of EUR 1.7 million from Bpifrance.
Fluxion Biosciences, Inc. announced the presentation of the first pilot study results aimed at isolating circulating tumor cells (CTCs) from early stage non-small cell lung cancer (NSCLC) patients obtained in collaboration with Dr. Max Diehn's lab at Stanford University. CTCs are cells that disseminate from primary tumors and contribute to the spread of the disease to other parts of the body.
Patients with acute coronary syndrome undergoing angioplasty who received the anticoagulant drug bivalirudin did not show significant improvements in either of two co-primary endpoints-a composite of rate of death, heart attack or stroke at 30 days, or a composite of those events plus major bleeding-as compared to patients receiving standard anticoagulation therapy, according to a study presented at the American College of Cardiology's 64th Annual Scientific Session.
Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has approved XIAFLEX (collagenase clostridium histolyticum, or CCH), an in-office, biologic for the treatment of Peyronie's disease. XIAFLEX is the first and only FDA-approved treatment proven effective for PD in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Debra Lee Kaysen, PHD 300 Pasteur Dr, Stanford, CA 94305-2200 Ph: (650) 723-4000 | Dr Debra Lee Kaysen, PHD 300 Pasteur Dr, Stanford, CA 94305-2200 Ph: (650) 723-4000 |
News Archive
TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today announces the receipt of EUR 1.7 million from Bpifrance.
Fluxion Biosciences, Inc. announced the presentation of the first pilot study results aimed at isolating circulating tumor cells (CTCs) from early stage non-small cell lung cancer (NSCLC) patients obtained in collaboration with Dr. Max Diehn's lab at Stanford University. CTCs are cells that disseminate from primary tumors and contribute to the spread of the disease to other parts of the body.
Patients with acute coronary syndrome undergoing angioplasty who received the anticoagulant drug bivalirudin did not show significant improvements in either of two co-primary endpoints-a composite of rate of death, heart attack or stroke at 30 days, or a composite of those events plus major bleeding-as compared to patients receiving standard anticoagulation therapy, according to a study presented at the American College of Cardiology's 64th Annual Scientific Session.
Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has approved XIAFLEX (collagenase clostridium histolyticum, or CCH), an in-office, biologic for the treatment of Peyronie's disease. XIAFLEX is the first and only FDA-approved treatment proven effective for PD in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy.
› Verified 9 days ago
Krishna Govinda Kary, PH.D. Psychologist Medicare: Medicare Enrolled Practice Location: 300 Pasteur Dr, Stanford, CA 94305 Phone: 650-723-4000 | |
Dr. Emily Eloise Livermore, PSYD Psychologist Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, Stanford, CA 94305 Phone: 650-723-4000 | |
Dr. Catherine Benedict, PHD Psychologist Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, Stanford, CA 94305 Phone: 650-723-4000 | |
Dr. Jennifer Marie Phillips, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 401 Quarry Rd, Stanford, CA 94305 Phone: 650-723-5511 Fax: 650-723-5531 | |
Peter Karzmark, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 300 Pasteur Dr, Stanford, CA 94305 Phone: 650-723-4000 | |
Julie Tinklenberg, M.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 866 Campus Dr, Stanford, CA 94305 Phone: 650-723-3785 | |
Dr. Jessica Megan Jones, PSY.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 401 Quarry Road, Stanford, CA 94305 Phone: 650-380-7223 Fax: 650-723-5531 |